Loading...
RSS feeds allow Web site content to be gathered via feed reader software. Click the subscribe link to obtain the feed URL for this page. The feed will update when new content appears on this page.
Highlights

A collection of news and information related to Sanofi-Aventis published by this site and its partners.

Sort By: Relevancy | Date | Type
Displaying items 1-12 of 17
» View all items
    Mar 22, 2013 |Story| Los Angeles Times

  1. Sequestration: California may lose $180 million in science research

    California stands to lose about $180 million in medical and scientific research funding under sequestration cuts, the most of any state, according to a group of biomedical researchers.
    California stands to lose about $180 million in medical and scientific research funding under sequestration cuts, the most of any state, according to a group of biomedical researchers. Sequestration, which went into effect March 1 after Congress...

    Tags: Diabetes, Research, Science and Technology, Medical Research, U.S. Congress

    2. Feb 28, 2012 |Story| Los Angeles Times

  2. Sleeping pills linked to higher risk of cancer, death, study says

    A new study suggests that the 6% to 10% of Americans who use prescription sleep medications such as zolpidem (Ambien), temazepam (Restoril), eszopiclone (Lunesta) and zaleplon (Sonata) are more likely to develop cancer, and far more likely to die prematurely, than those who take no sleep aids.
    A new study suggests that the 6% to 10% of Americans who use prescription sleep medications such as zolpidem (Ambien), temazepam (Restoril), eszopiclone (Lunesta) and zaleplon (Sonata) are more likely to develop cancer, and far more likely to die...

    Tags: Diabetes, Pharmaceuticals, Cancer, Social Sciences, Lungs and Airways

    3. May 15, 2011 |Story| Los Angeles Times

  3. Stand Up to Type 2

     
      In December of 2007, I was diagnosed with Type 2 diabetes. I initially felt scared and confused, but then I committed to educating myself about diabetes and worked with my doctor to determine the overall diabetes treatment plan that was right for me....

    Tags: Diabetes, Diseases and Illnesses, Health Treatments, Diabetes Treatment, Chemical Industry

    4. Dec 5, 2010 |Story| Los Angeles Times

  4. BlackBerry vs. iPhone: What's in your pocket?

    There was a time when BlackBerrys grew wild.
    There was a time when BlackBerrys grew wild. They were everywhere: boardrooms, restaurants and kitchen tables. The dark little devices would vibrate every time a new e-mail arrived, delivering a tiny thrill that millions of employees came to both...

    Tags: Economy, Business and Finance, Career and Workplace, Consumers, Surgery, Real Estate

    5. Sep 8, 2010 | Los Angeles Times

  5. American Kennel Club, Pfizer Inc. announce partnership for dog disease research

    L.A. Unleashed
    TRENTON, N.J. — Pfizer Inc. said Wednesday its animal health unit and the American Kennel Club Canine Health Foundation entered an exclusive partnership on new areas of research on dog diseases and treatments. Pfizer said the goal is to strengthen......
    6. Sep 29, 2009 | Los Angeles Times

  6. First swine flu shots shipped

    Booster Shots
    The first injectable vaccines against the pandemic H1N1 influenza virus have been shipped, about two weeks earlier than expected. "The first truck left today" from a factory in Swiftwater, Pa., Chris Viehbacher, chief executive of the French...
    7. Oct 28, 2009 | Los Angeles Times

  7. Obesity drugs lumber toward marketplace

    Booster Shots
    About this time last year, we were reporting on the failure of several investigational weight-loss medications. They included Sanofi-Aventis' rimonabant as well as two other drugs that aimed to work by blocking cannabinoid receptors in the brain. However,...
    8. Nov 10, 2009 | Los Angeles Times

  8. FDA commissioner reassures doctors about swine flu vaccine safety

    Booster Shots
    Dr. Margaret A. Hamburg, commissioner of the Food and Drug Administration, sent a letter to all U.S. physicians today thanking them for their help in combating the pandemic H1N1 influenza virus and reassuring them about the safety of the vaccine......
    9. Dec 15, 2009 | Los Angeles Times

  9. 800,000 swine flu doses for very young children recalled, but it's not a safety issue

    Booster Shots
    Vaccine manufacturer Sanofi-Aventis is recalling 800,000 doses of vaccine against the pandemic H1N1 virus meant for children younger than 3 because the vaccine has lost potency since it was shipped from the factory. "This is non-safety related, but is...
    10. Dec 21, 2009 | Los Angeles Times

  10. What's in Gold Bond? A powder by any other name …

    Booster Shots
    Paris-based drug giant Sanofi-Aventis made waves today when it announced the $1.9 billion acquisition of Chattem Inc., humble maker of Selsun Blue shampoo and Gold Bond medicated powder. Business pundits wondered what a high-end international...
    11. Dec 23, 2009 |Story| Los Angeles Times

  11. More H1N1 Vaccine Recalled

    Vaccine maker MedImmune has voluntarily recalled 13 lots of vaccine against the pandemic H1N1 influenza because they have lost some potency since they were manufactured, the company said Tuesday.
    Los Angeles Times
    Vaccine maker MedImmune has voluntarily recalled 13 lots of vaccine against the pandemic H1N1 influenza because they have lost some potency since they were manufactured, the company said Tuesday. "This is not a safety issue," Norman Baylor, director of...

    Tags: Gaithersburg (Montgomery, Maryland), MedImmune Inc., Swine Flu, Vaccines, Pharmaceuticals

    12. Mar 4, 2010 | Los Angeles Times

  12. New drug offers last-ditch hope for prostate cancer patients

    Booster Shots
    An experimental drug called cabazitaxel increases survival by 30% in men with advanced prostate cancer that has become resistant to all other forms of treatment, researchers will report Friday at a San Francisco meeting called the 2010 Genitourinary...
 1  2 • Next >
Original site for Sanofi-Aventis topic gallery.
Advertisement